As a generally held principle, mere investment or ownership interest in a company does not expose the investor to liability for acts undertaken by the company. However, that principle is being called into question in the context of private equity firms investing in healthcare companies. In two recent cases, healthcare companies along with their sole or majority private equity firm owners settled False Claims Act (“FCA”) cases. These cases illustrate the risk that private equity investors in the healthcare space may face under the FCA, particularly to the extent that they actively manage their portfolio companies.
Trending
- Multitarget Stool DNA Versus Fecal Immunochemical Testing: A National Assessment of Follow-Up Colonoscopy by Race and Ethnicity (National Comprehensive Cancer Network)
- Physician Fee Schedule 2027: What physicians need to know now (Medical Economics)
- Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer (Business Wire)
- What Happens to Independent Medicine When Private Equity Shows Up With a Checkbook (MedCity News)
- AGA launches AI-powered virtual assistant for gastroenterology and hepatology care (News Medical)
- AMSURG Acquires 5 Endoscopy Centers in North Carolina (ASC News)
- Hawaii mandates free follow-up colonoscopies, wipes $91M in medical debt (Becker’s Healthcare)
- Endo Tools Therapeutics Secures $23 million in Series C Financing to Advance The endomina® technology and Commercialization of New endomina EZFuse System (Endo Tools Therapeutics)
